Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​Voluntary withdrawal of Blenrep® from U.S. market

January 13, 2023

​On November 22, 2022, GlaxoSmithKline decided to voluntarily withdraw the Biologic License Application (BLA) for Blenrep® (belantamab mafodotin-blmf).  

How does this affect our members?

GlaxoSmithKline will send letters to providers who prescribe Blenrep to notify them about this decision. These letters will include information about the compassionate use of Blenrep for individuals who are currently receiving the drug. Independence Blue Cross and Independence Administrators (collectively, Independence) will continue to cover Blenrep for these members. New requests for Blenrep will not be covered by Independence.

For more information

The complete statement on the U.S. market withdrawal of Blenrep, including details about the compassionate use program, is available on the GlaxoSmithKline website. ​

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.